<DOC>
	<DOC>NCT00818571</DOC>
	<brief_summary>This study assess the pharmacokinetics of vildagliptin in mild, moderate and severe renal impaired patients</brief_summary>
	<brief_title>Pharmacokinetics of Vildagliptin in Mild, Moderate and Severe Renal Impaired Patients</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>Patients with mild (CrCl from 50 to â‰¤80 ml/min), moderate (CrCl from 30 to &lt;50 ml/min) and severe (CrCl of &lt;30 ml/min) renal function, preferably type 2 diabetic and matching healthy volunteers CrCl of &gt;80 ml/min Type 1 diabetes, diabetes that is a result of pancreatic injury, or secondary forms of diabetes, acute metabolic diabetic complications, treatment of a DPP4 inhibitor 30 days prior to baseline, renal transplant history Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Renal impairment</keyword>
	<keyword>Diabetes</keyword>
	<keyword>vildagliptin</keyword>
	<keyword>Galvus</keyword>
	<keyword>Eucreas</keyword>
</DOC>